News headlines about CONMED Corporation (NASDAQ:CNMD) have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. CONMED Corporation earned a media sentiment score of 0.03 on Accern’s scale. Accern also gave news coverage about the medical technology company an impact score of 47.7668735312736 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news articles that may have effected Accern’s analysis:
- Insider Selling: CONMED Corporation (CNMD) Director Sells 3,000 Shares of Stock (americanbankingnews.com)
- ETFs with exposure to CONMED Corp. : August 15, 2017 (finance.yahoo.com)
- Gal Gadot Sings After ‘Wonder Woman’ Makes $400M Domestically (fishinghd.com)
- See what the IHS Markit Score report has to say about Conmed Corp. (finance.yahoo.com)
CONMED Corporation (CNMD) opened at 48.60 on Friday. The firm has a 50 day moving average of $50.18 and a 200-day moving average of $47.50. CONMED Corporation has a 12 month low of $37.60 and a 12 month high of $52.82. The firm has a market cap of $1.36 billion, a P/E ratio of 86.94 and a beta of 0.67.
CONMED Corporation (NASDAQ:CNMD) last issued its earnings results on Wednesday, July 26th. The medical technology company reported $0.41 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.41. The business had revenue of $197.20 million for the quarter, compared to the consensus estimate of $194.50 million. CONMED Corporation had a net margin of 2.02% and a return on equity of 8.38%. The business’s quarterly revenue was up 2.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.47 earnings per share. On average, equities research analysts forecast that CONMED Corporation will post $1.87 earnings per share for the current year.
A number of research firms recently issued reports on CNMD. Needham & Company LLC boosted their target price on shares of CONMED Corporation from $48.00 to $54.00 and gave the company a “buy” rating in a research report on Thursday, April 27th. BidaskClub upgraded shares of CONMED Corporation from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 10th. TheStreet upgraded shares of CONMED Corporation from a “c+” rating to a “b-” rating in a research report on Thursday, August 3rd. Ladenburg Thalmann Financial Services downgraded shares of CONMED Corporation from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $50.00 to $48.00 in a research report on Thursday, April 27th. Finally, Zacks Investment Research upgraded shares of CONMED Corporation from a “sell” rating to a “hold” rating in a research report on Friday, April 28th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company’s stock. CONMED Corporation has a consensus rating of “Hold” and an average price target of $49.33.
COPYRIGHT VIOLATION NOTICE: “CONMED Corporation (NASDAQ:CNMD) Earns Daily News Impact Rating of 0.03” was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://stocknewstimes.com/2017/08/19/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-conmed-corporation-nasdaqcnmd-share-price-updated-updated.html.
In other news, Director Dirk Kuyper sold 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 13th. The shares were sold at an average price of $52.24, for a total value of $52,240.00. Following the completion of the transaction, the director now owns 10,739 shares of the company’s stock, valued at $561,005.36. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Jo Ann Golden sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $50.00, for a total transaction of $150,000.00. Following the completion of the sale, the director now owns 19,782 shares of the company’s stock, valued at $989,100. The disclosure for this sale can be found here. 2.62% of the stock is owned by company insiders.
About CONMED Corporation
CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.
Receive News & Ratings for CONMED Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
